Alnylam Pharmaceuticals | ALNY - Operating Expenses

Stock Price
286.98
Daily Change
-6.47 -2.20%
Monthly
-10.36%
Yearly
0.59%
Q2 Forecast
281.21

Alnylam Pharmaceuticals reported $898.54M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 272.68M 6.08M Mar/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
Arrowhead Research USD 215M 8.23M Mar/2026
BioCryst Pharmaceuticals USD -553.84M 700.01M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Incyte USD 5.62B 4.5B Mar/2026
Ionis Pharmaceuticals USD 364M 54M Mar/2026
Moderna USD 1.78B 242M Mar/2026
Neurocrine Biosciences USD 599.9M 22.3M Mar/2026
Novartis USD 9.8B 23M Dec/2025
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 10.71B 1.32B Dec/2025
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
Takeda JPY 1.11T 85.29B Mar/2026
Tectonic Therapeutic USD 21.52M 374K Dec/2025
Ultragenyx Pharmaceutical USD 305M 16M Mar/2026
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026
Xencor USD 82.38M 513K Mar/2026